Oryzon Genomics S.A. (BME:ORY)
Spain
· Delayed Price · Currency is EUR 3.140
-0.080 (-2.48%)
At close: Feb 27, 2026
Oryzon Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | - | 7.62 | 15.69 | 16.78 | 12.07 | Upgrade
|
| Revenue Growth (YoY) | - | -51.43% | -6.50% | 38.97% | 3.65% | Upgrade
|
| Cost of Revenue | - | 0.31 | 0.27 | 0.5 | 0.85 | Upgrade
|
| Gross Profit | - | 7.31 | 15.42 | 16.28 | 11.22 | Upgrade
|
| Selling, General & Admin | 5.59 | 3.77 | 3.99 | 3.81 | 4.17 | Upgrade
|
| Research & Development | 14.81 | - | - | - | - | Upgrade
|
| Other Operating Expenses | - | 8.05 | 16.31 | 18.16 | 14.86 | Upgrade
|
| Operating Expenses | 20.4 | 11.97 | 20.46 | 22.16 | 19.2 | Upgrade
|
| Operating Income | -20.4 | -4.66 | -5.04 | -5.87 | -7.98 | Upgrade
|
| Interest Expense | - | -1.27 | -2.09 | -1.2 | -0.52 | Upgrade
|
| Interest & Investment Income | - | 0.12 | 0.04 | 0.01 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.09 | 0.11 | 0.25 | 0.32 | Upgrade
|
| Other Non Operating Income (Expenses) | 13.69 | 0.05 | 0.23 | -0.21 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -6.71 | -5.85 | -6.76 | -7.01 | -8.17 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0 | Upgrade
|
| Other Unusual Items | - | 0.08 | 0.02 | 0.01 | 0.01 | Upgrade
|
| Pretax Income | -6.71 | -5.77 | -6.75 | -7.01 | -8.17 | Upgrade
|
| Income Tax Expense | -3.65 | -1.97 | -3.04 | -2.48 | -2.84 | Upgrade
|
| Net Income | -3.06 | -3.79 | -3.71 | -4.52 | -5.33 | Upgrade
|
| Net Income to Common | -3.06 | -3.79 | -3.71 | -4.52 | -5.33 | Upgrade
|
| Shares Outstanding (Basic) | 74 | 65 | 61 | 55 | 53 | Upgrade
|
| Shares Outstanding (Diluted) | 74 | 65 | 61 | 55 | 53 | Upgrade
|
| Shares Change (YoY) | 14.85% | 6.35% | 10.10% | 4.80% | - | Upgrade
|
| EPS (Basic) | -0.04 | -0.06 | -0.06 | -0.08 | -0.10 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.06 | -0.06 | -0.08 | -0.10 | Upgrade
|
| Free Cash Flow | - | -5.89 | -0.64 | -2.06 | -4.32 | Upgrade
|
| Free Cash Flow Per Share | - | -0.09 | -0.01 | -0.04 | -0.08 | Upgrade
|
| Gross Margin | - | 95.89% | 98.28% | 97.04% | 92.97% | Upgrade
|
| Operating Margin | - | -61.18% | -32.16% | -35.02% | -66.07% | Upgrade
|
| Profit Margin | - | -49.81% | -23.63% | -26.96% | -44.15% | Upgrade
|
| Free Cash Flow Margin | - | -77.32% | -4.05% | -12.25% | -35.82% | Upgrade
|
| EBITDA | -20.25 | -4.53 | -4.9 | -5.72 | -7.82 | Upgrade
|
| EBITDA Margin | - | -59.47% | -31.24% | -34.08% | -64.81% | Upgrade
|
| D&A For EBITDA | 0.15 | 0.13 | 0.14 | 0.16 | 0.15 | Upgrade
|
| EBIT | -20.4 | -4.66 | -5.04 | -5.87 | -7.98 | Upgrade
|
| EBIT Margin | - | -61.18% | -32.16% | -35.02% | -66.07% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.